Nonsignificant Increase in Birth Defects Seen With Direct Potable Reuse
By Elana Gotkine HealthDay Reporter
WEDNESDAY, March 27, 2024 -- Following implementation of direct potable reuse (DPR), which involves adding purified wastewater that has not passed through an environmental buffer into a water distribution system, there was a non-statistically significant increase in birth defect prevalence, according to a study published in the April issue of Environmental Epidemiology.
Jeremy M. Schraw, Ph.D., from Baylor College of Medicine in Houston, and colleagues examined whether the introduction of DPR for certain public water systems in Texas was associated with changes in the prevalence of birth defects. Data were obtained on maternal characteristics for all live births and birth defect cases, regardless of pregnancy outcome, from 2003 to 2017. Changes in birth defect prevalence (per 10,000 live births) following adoption of DPR by four counties in mid-2013 were modeled using the ridge augmented synthetic control method.
The researchers found that the prevalence of all birth defects collectively and congenital heart disease increased, but the increase was not statistically significant (average treatment effect in the treated, 53.6 and 287.3, respectively) since June 2013. There was no change observed in the estimated prevalence of neural tube defects.
"Our study does not establish a causal role for DPR with respect to birth defects, but it does raise the suggestion that there may be a link between direct potable reuse and an elevated risk of birth defects at the population level, specifically congenital heart defects," Schraw said in a statement.
One author reported previously owning shares in a water sector mutual fund that he had divested.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.